SELLAS Advances SLS009 Trial with First Patient Enrollment, Meeting Key Checkpoint Amid Lingering Risks

What happened

SELLAS announced the enrollment of the first patient in its newly diagnosed first-line AML trial for SLS009, targeting 80 patients unlikely to benefit from standard therapy. This news confirms the company's ability to meet a critical near-term execution milestone, as the DeepValue report highlighted the need for SLS009 trial initiation by Q1 2026 to sustain investor confidence. However, the primary value driver remains the REGAL Phase 3 trial, which still awaits the 80th OS event for final analysis, with only 72 events reported as of late December 2025 and timeline uncertainty due to partner disputes. The company continues to rely on dilutive financing, with share count increasing to 170.3 million as of early January 2026, capping per-share upside even if clinical progress occurs. Despite this step forward, the broader investment thesis hinges on REGAL's event accrual and financing discipline, which remain unaddressed.

Implication

This milestone validates management's guidance on SLS009 trial start, slightly easing skepticism about operational delays and supporting the narrative of a second asset in development. It does not alter the binary nature of the REGAL Phase 3 catalyst, which is the dominant driver of equity value and still lacks the 80th event announcement. Ongoing dilution from warrant exercises and inducements, as detailed in filings, threatens per-share economics even if SLS009 progresses, limiting upside potential. Investors should monitor for the REGAL 80th event PR and further financing disclosures, as absence of these could compress the catalyst premium. Overall, this is a positive but incremental development that fails to shift the risk-reward profile without concurrent REGAL progress.

Thesis delta

The enrollment of the first patient in SLS009 confirms execution on a key near-term milestone, slightly reducing operational risk and aligning with the base scenario of the DeepValue report. However, the core investment thesis remains unchanged, as the REGAL Phase 3 catalyst and dilution dynamics continue to dominate valuation and risk assessment. No material shift in the overall 'WAIT' rating or conviction level is warranted until REGAL progresses or financing terms improve.